简介：ELAD circulates patient plasma through hollow fiber cartridges containing metabolically active， immortalized C3A human liver cells of hepatoblastoma origin. A prior randomized， controlled clinical study of ELAD in China demonstrated a significant improvement in transplant-free survival (TFS) in subjects with acute-on-chronic liver failure (ACLF).